SCHEMBL4288720

SCHEMBL4288720

CCCOc1cc(N)ccc1C(=O)Nc1nccs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.58
ALOX15 P16050 1/20 0.58
RAB9A P51151 7/20 0.54
NPC1 O15118 6/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
SMN1; SMN2 Q16637 5/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
LMNA P02545 1/20 0.53
RECQL P46063 1/20 0.53
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
ADORA2A P29274 1/20 0.51
ADORA1 P30542 1/20 0.51
KCNMA1 Q12791 1/20 0.50
GCK P35557 1/20 0.50
HSD17B10 Q99714 1/20 0.48
HPGD P15428 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289694 0.91 RAB9A (0.56) MAPK1ALOX15RAB9ANPC1POLB
SCHEMBL4286251 0.86 RAB9A (0.71) MAPK1ALOX15RAB9ANPC1POLB
SCHEMBL17274993 0.83 MAPK1 (0.81) MAPK1ALOX15RAB9ANPC1SMN1; SMN2
SCHEMBL4290165 0.83 ADORA2A (0.64) MAPK1ALOX15RAB9ANPC1POLB
SCHEMBL4286409 0.83 MAPT (0.57) MAPK1ALOX15RAB9ANPC1POLB
SCHEMBL4299463 0.80 ADORA2A (0.80) MAPK1ALOX15RAB9ANPC1POLB
SCHEMBL4290003 0.80 ADORA2A (0.62) MAPK1ALOX15RAB9ANPC1POLB
SCHEMBL4292861 0.80 RAB9A (0.62) MAPK1RAB9ANPC1POLBMAPT
SCHEMBL4295738 0.79 NPC1 (0.66) RAB9ANPC1POLBMAPTSMN1; SMN2
SCHEMBL4290960 0.77 EPHX2 (0.57) MAPK1ALOX15RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 MAPK1 3788/4885ALOX15 1975/4885RAB9A 2380/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 MAPK1 3788/4885ALOX15 1975/4885RAB9A 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.